Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
A targeted drip catches you up faster than slow sipping at home
They differ by: receptor profile approval status trial design tolerability and how much real-world evidence exists today That is why the most honest ranking is not 1st, 2nd, 3rd. It is: semaglutide is the proven single-agonist benchmark tirzepatide is the current approved leader retatrutide is the Phase 3 investigational drug most likely to reshape the market if the remaining data hold Sources New England Journal of Medicine / PubMed: STEP 1 semaglutide trial FDA: Wegovy cardiovascular-risk indication and current indication summary FDA: Zepbound approval for chronic weight management Eli Lilly: SURMOUNT-5 complete results Eli Lilly: TRIUMPH-4 Phase 3 retatrutide results Eli Lilly: retatrutide Phase 3 diabetes results and dysesthesia signal Lilly FAQ: what to know about retatrutide
One clinic
Supplementary Table 4 Adverse events by baseline eGFR
